Pharmacogenetic approaches to cognitive enhancement in schizophrenia. Review uri icon

Overview

abstract

  • Research in the area of pharmacogenetics in psychiatry is aimed at identifying clinically relevant genetic variations that can predict treatment response. Ultimately, the goal is to individualize treatment in order to optimize outcome in disorders in which incomplete treatment response is common. Positive symptoms in patients with schizophrenia appear to be the most amenable to the currently available agents; however, negative symptoms and cognitive deficits frequently persist even when frank psychosis is well controlled. Given the relationship between these persistent traits and functional disability in schizophrenia, efforts are under way to directly target cognitive impairment and negative symptoms pharmacologically in order to improve quality of life. To date, most pharmacogenetic studies of schizophrenia have been focused on predicting clinical efficacy and side effects. In this review, we discuss the potential use of cognition as a primary outcome measure of interest in future pharmacogenetic trials of schizophrenia.

publication date

  • January 1, 2011

Research

keywords

  • Antipsychotic Agents
  • Cognition
  • Pharmacogenetics
  • Schizophrenia

Identity

Scopus Document Identifier

  • 79958037920

Digital Object Identifier (DOI)

  • 10.3109/10673229.2011.581899

PubMed ID

  • 21631157

Additional Document Info

volume

  • 19

issue

  • 3